Preliminary Study Results Of Multiple Drug Resistance In Patients With Advanced Types Of Colorectal Cancer

S Navruzov, S Abdujapparov, D Pulatov, H Islamov, Sh Matniyazova, E Akbarov


In the department of coloproctology of NORC MH RUz 17 patients with disseminated forms of colorectal cancer was made the study of oncogenes and complex treatment by 2 protocols using FOLFOX-4 regime and FOLFIRI regime. In second protocol there used 2 sessions of endolymphatical polychemotherapy FOLFOX-4 regime against EHF-hyperthermia. All patients were performed additional investigations directed to study the presence of multiple drug resistance in them where definition of р53, bcl-2 oncogene expression. In our observations we followed resistance to FOLFOX-4 scheme in 4 patients, and to FOLFIRI scheme in 2 cases. In our studies hyperexpression of oncoproteine  р53 was correlated with the effect of conducted therapy whereas hyperexpression of oncoproteine bcl-2 showed therapy resistance.



Colorectal Cancer, Multiple Drug Resistance, (Mdr) Oncogenes Р53, Bcl-2

Full Text:



Saprin A.N.,. Kalinina E.V., Babenko M.D. //Advances of biol.chemisrtry. 1996: Т.36: .213-265.

Sergeeva N.S.. oncol. journ. 2006: №3:51-55

Stavrovskaya A.A.. //Biochemistry. 2000:V65:№1:112-126.

Kupeshov O.K., Tsib A.F., Mardinskiy Yu.S., Berdov B.A. //Rus. oncol. Journ -2002: №4:48.51

Cale S.P.C. // Cancer J. Physiol. Pharmacol. 2002: V70: №3:80-81

Cordon-Cardo C., Obrien J.P., Boccia J. et all. //J.Histochem. Cytochem. 2000: V38: №9:1277-1287

Yang R.V. //Cancer. 2001: V65: №3:814-818



  • There are currently no refbacks.

Print ISSN 1804-5804, Online ISSN 1804-9702

(c) 2018 CBU,o.p.s.